PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: KGF alternative peptide (FGFR2b agonist)
(Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called ...
EurekAlert!24d
FXR cyclic peptide antagonists as a novel strategy for MASH treatment
The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism. Bile acids are natural ligands of FXR, which bind to the ...
Hosted on MSN22d
Novel cyclic peptide antagonist can be a promising therapeutic approach for MASH
Cyclic peptides, which combine characteristics of both small molecules and proteins, have emerged as significant molecules for regulating protein–protein interactions (PPIs). Recent studies have ...
Pharmaceutical Commerce12d
AstraZeneca Financially Commits $2.5B Toward New R&D Center
1. AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing.
Contract Pharma13d
AstraZeneca to Invest $2.5B in New Global R&D Center in Beijing
Investment includes agreements with Harbour BioMed, Syneron Bio and BioKangtai
.
Nature2y
Breakthrough technologies transform the discovery and development of peptide drugs
During the early months of the COVID-19 pandemic, Pepticom identified the opportunity to apply its artificial intelligence (AI) platform to rapidly generate high-quality peptide molecules that ...